Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti‐HBc: implications for future HBV screening policy

Kuhns, Mary C.; Kleinman, Steven; McNamara, Anne L.; Rawal, B. D.; Glynn, Simone A.; Busch, Michael P.

doi:10.1111/j.1537-2995.2004.04055.x

Cited by 108 publications

(114 citation statements)

References 14 publications

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…Ozaras et al (2008) suggested that the HBsAg level was correlated with HBV DNA, and that it could replace HBV DNA to monitor the efficacy of pegylated interferon in the presence or absence of lamivudine marker. On the other hand, Ozdil et al (2009) reported a negative correlation between HBV DNA and HBsAg in non-cirrhotic chronic HBV-infected patients, whereas Kuhns et al (2004) found no correlation between HBsAg and HBV DNA in 200 blood samples. This could be attributed to various factors: 1) differences in the sensitivity of the HBV DNA detection protocol; most previous studies set a lower limit of detection as 103 copies/mL (not 1.16 x 10 2 copies/mL); 2) antiviral treatment (that some of the patients were subjected to) can induce mutations in the HBsAg sequence; viral variants appear as a result of endogenous (host immunity) and/or exogenous (immune-prophylaxis and antiviral therapy) factors (Locarnini and Zoulim, 2010); and 3) the high spontaneous error rate in the reverse transcriptase induces mutations in the virus, such as the preS/S variants (Pollicino et al, 2012).…”

Section: Discussionmentioning

confidence: 97%

Correlation between hepatitis B virus DNA levels and diagnostic tests for HBsAg, HBeAg, and PreS1-Ag in chronic hepatitis B

et al. 2016

View full text Add to dashboard Cite

ABSTRACT. The aim of this study was to investigate the diagnostic value of the serum markers HBsAg and HBeAg and PreS1 protein (PreS1-Ag) in quantifying the levels of hepatitis B virus (HBV) DNA in patients with chronic hepatitis B (CHB). One thousand CHB patients were recruited from Beijing You'an Hospital between June and December 2012. Serum HBsAg and HBeAg levels were detected by electrochemiluminescence immunoassay. Enzyme-linked immunosorbent assay and fluorescence quantitative PCR were used to determine the level of PreS1-Ag and HBV DNA, respectively. We observed a low correlation between HBsAg and HBV DNA (r = 0.172, P < 0.001) expression; however, the correlation coefficient increased gradually with the increase in HBV DNA levels, and was more significant when HBV DNA log 10 > 7 (r = 0.597, P < 0.001). Additionally, HBsAg and HBV DNA showed a significant positive correlation in the HBeAg+ group (r = 0.321, P < 0.001), whereas no correlation was observed in the HBeAg-group (r = -0.016, P = 0.825). HBV DNA expression was correlated with HBeAg (c 2 = 83.07, P < 0.001) and PreS1-Ag (c 2 = 36.01, P < 0.001). HBV DNA-positive rate was higher in HBeAg/PreS1-Ag++ patients (72.26%) than that in the single-positive groups (P < 0.001). Therefore, serum HBsAg is not a good marker for the prediction of HBV replication, and co-detection of HBeAg and PreS1-Ag, which can better predict HBV DNA replication, can be used as a reliable method for the clinical diagnosis and treatment of CHB.

show abstract

Section: Discussionmentioning

confidence: 97%

Correlation between hepatitis B virus DNA levels and diagnostic tests for HBsAg, HBeAg, and PreS1-Ag in chronic hepatitis B

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Although HBsAg assays are more sensitive in detecting HBV window-period infections, anti-HBc test can detect chronic carriers with low-level viremia without detectable HBsAg. The first few years of adding HBV NAT to routine screening of blood donations in the USA and Germany showed only a small yield [12,36], and other studies pointed out that 3% of HBV-infected donations would remain undetected even by ID NAT, thus reinforcing the need to maintain the HBsAg marker for routine blood screening [91]. More recently, PRISM CLIA claimed a 60% reduction of the HBV residual risk over MP NAT, from 1 : 385.555 to 1 : 610.488 [92].…”

Section: Discussionmentioning

confidence: 99%

Residual Risk of Hepatitis-B-Infected Blood Donations: Estimation Methods and Perspectives

Kupek

2013

ISRN Infectious Diseases

View full text Add to dashboard Cite

Despite a considerable reduction of the risk of HBV-infected blood donation entering blood supply (residual risk) due to improved screening by HBV NAT in the developed countries, the bulk of the people with HBV living in the developing countries still needs to be screened by serologic tests such as HBsAg and anti-HBc. Many of these countries lack resources for implementing NAT and are likely to remain so in the next decade or longer, thus depending on the HBV residual risk monitoring based on serologic testing and corresponding estimation methods. This paper reviews main HBV residual risk findings worldwide and the methods based on serology used for their calculation with repeat donors, as well as their extension to the first-time donors. Two artificial datasets with high (4.36%) and low (0.48%) HBV prevalence were generated to test the performance of five methods: the original incidence/window-period model based solely on HBsAg, its modification by Soldan in 2003, the Müller-Breitkreutz model, the HBsAg yield model, and its extension to include anti-HBc seroconversions within a year. The last model was closest to the true values of residual risk and had smallest variation of the estimates in both high and low prevalence data. It may be used for residual risk evaluation in relatively small samples, such as regional blood banks data.

show abstract

“…Bu çalışmaların birçoğunda HBsAg ve HBV DNA düzeyleri arasında pozitif korelasyon saptanmıştır (4,8,(15)(16)(17)(18). Bununla birlikte herhangi bir ilişkinin saptanmadığı (6,19,20) veya negatif ilişkinin saptandığı çalışmalar da (14) yayınlanmıştır. Biz çalışmamızda sadece HBsAg s/co değeri 400'e kadar olan hastalarda HBV DNA ile HBsAg arasında pozitif korelasyon saptarken tüm hastaları değerlendirdiğimizde negatif korelasyon olduğunu gördük.…”

Section: Discussionunclassified

Kronik Hepatit B Enfeksiyonu Olan Hastalarda HBsAg ve HBeAg Değerlerinin HBV DNA ve Alanin Aminotransferaz Düzeyleri ile Karşılaştırılması

Sağlık¹,

Mutlu²,

Öngüt³

et al. 2013

vhd

View full text Add to dashboard Cite

Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti‐HBc: implications for future HBV screening policy

Cited by 108 publications

References 14 publications

Correlation between hepatitis B virus DNA levels and diagnostic tests for HBsAg, HBeAg, and PreS1-Ag in chronic hepatitis B

Correlation between hepatitis B virus DNA levels and diagnostic tests for HBsAg, HBeAg, and PreS1-Ag in chronic hepatitis B

Residual Risk of Hepatitis-B-Infected Blood Donations: Estimation Methods and Perspectives

Kronik Hepatit B Enfeksiyonu Olan Hastalarda HBsAg ve HBeAg Değerlerinin HBV DNA ve Alanin Aminotransferaz Düzeyleri ile Karşılaştırılması

Contact Info

Product

Resources

About